Unity Biotechnology’s (UBX) Buy Rating Reiterated at HC Wainwright

Posted by James Quigley on Mar 13th, 2025

HC Wainwright reissued their buy rating on shares of Unity Biotechnology (NASDAQ:UBX – Free Report) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock. HC Wainwright also issued estimates for Unity Biotechnology’s Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at $0.23 EPS, FY2028 earnings at $0.68 EPS and FY2029 earnings at $0.88 EPS.

Separately, Chardan Capital assumed coverage on Unity Biotechnology in a research report on Friday, January 10th. They issued a “buy” rating and a $6.00 price objective for the company.

Check Out Our Latest Report on Unity Biotechnology

Unity Biotechnology Price Performance

Unity Biotechnology stock opened at $1.78 on Monday. The stock has a market capitalization of $29.99 million, a PE ratio of -1.36 and a beta of 1.02. Unity Biotechnology has a 12 month low of $0.94 and a 12 month high of $3.10. The business has a 50 day simple moving average of $1.88 and a 200-day simple moving average of $1.51.

Institutional Investors Weigh In On Unity Biotechnology

An institutional investor recently raised its position in Unity Biotechnology stock. Geode Capital Management LLC raised its holdings in Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 9.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 163,242 shares of the company’s stock after purchasing an additional 14,199 shares during the quarter. Geode Capital Management LLC owned 0.97% of Unity Biotechnology worth $240,000 as of its most recent SEC filing. 29.49% of the stock is owned by hedge funds and other institutional investors.

Unity Biotechnology Company Profile

(Get Free Report)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.